Open-Label Extension Study of Kuvan for Autism

Phase 2/3 Completed 41 enrolled The Children's Health Council BioMarin Pharmaceutical · collab

NaSingle-groupOpen-labelTreatment

Summary

This is an open-label extension study available only to subjects who completed an earlier double-blind, placebo-controlled study of sapropterin in children with autism.

Timeline

Start: 2009-08
Primary completion: 2011-12
Completion: 2012-03

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	sapropterin	Unknown	20 mg/kg	—

Open-Label Extension Study of Kuvan for Autism

Summary

Timeline

Drugs

Indications